Buy Danyelza (naxitamab-gqgk) Online

Danyelza (Naxitamab-gqgk) Injection is a GD2-binding monoclonal antibody used, along with granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have shown a partial response, minor response, or stable disease to prior therapy.

Dosage: The recommended dosage of naxitamab-gqgk is 3 mg/kg daily (up to 150 mg daily) on Days 1, 3, and 5 of each treatment cycle, administered as an intravenous infusion after dilution in combination with GM-CSF subcutaneously. Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks. Subsequent cycles may be repeated every 8 weeks. Discontinue your naxitamab-gqgk dosage and GM-CSF for disease progression or unacceptable toxicity.

Side Effects: The most commonly reported danyelza injection side effects (≥25%) include:

  • Pain
  • Tachycardia
  • Vomiting
  • Cough
  • Nausea
  • Diarrhea
  • Decreased appetite
  • Hypertension
  • Fatigue
  • Urticaria
  • Pyrexia
  • Headache
  • Injection site reaction
  • Edema
  • Anxiety
  • Localized edema
  • Irritability
  • Erythema multiforme
  • Peripheral neuropathy
  • Infusion-related reaction

Warnings and Precautions:

  • The danyelza injection uses is restricted in patients with a history of severe hypersensitivity reaction to it.
  • Monitor patients for signs/symptoms of infusion reactions during and for at least 2 hours following completion of each naxitamab-gqgk infusion.
  • Monito+9r patients for blood pressure during infusion, and at least daily on Days 1-8 of each cycle of danyelza injection and assess for complications of hypertension including RPLS.
  • The mechanism of action of danyelza suggest that it may cause fetal harm if administered to a pregnant woman.
  • Women should avoid breastfeeding during treatment with naxitamab-gqgk and for two months following the final dose.